Development and application of PI3K assays for novel drug discovery

Bibliography

• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28(6):1075-83
   PubMed Web of Science ®Google Scholar
• Eisenreich A, Rauch U. PI3K inhibitors in cardiovascular disease. Cardiovasc Ther 2011;29(1):29-36
   PubMed Web of Science ®Google Scholar
• Wymann MP, Solinas G. Inhibition of phosphoinositide 3-kinase gamma attenuates inflammation, obesity, and cardiovascular risk factors. Ann N Y Acad Sci 2013;1280:44-7
   PubMed Web of Science ®Google Scholar
• Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/mTOR pathway in pediatric hematologic malignancies. Front Oncol 2014;4:108
   PubMedGoogle Scholar
• Jackson SP, Yap CL, Anderson KE. Phosphoinositide 3-kinases and the regulation of platelet function. Biochem Soc Trans 2004;32(Pt 2):387-92
   PubMedGoogle Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7(8):606-19
   PubMed Web of Science ®Google Scholar
• Hawkins PT, Anderson KE, Davidson K, et al. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006;34(Pt 5):647-62
   PubMed Web of Science ®Google Scholar
• Hirsch E, Costa C, Ciraolo E. Phosphoinositide 3-kinases as a common platform for multi-hormone signaling. J Endocrinol 2007;194(2):243-56
   PubMed Web of Science ®Google Scholar
• Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res 2009;82(2):261-71
   PubMed Web of Science ®Google Scholar
• Vogt PK, Hart JR, Gymnopoulos M, et al. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol 2010;347:79-104
   PubMed Web of Science ®Google Scholar
• Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 2013;31:675-704
   PubMed Web of Science ®Google Scholar
• Gong C, Liao H, Wang J, et al. LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human osteosarcoma via down-regulation of PI3K activity. Asian Pac J Cancer Prev 2012;13(7):3103-7
   PubMed Web of Science ®Google Scholar
• Fougerat A, Gayral S, Malet N, et al. Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis? Clin Sci (Lond) 2009;116(11):791-804
   PubMed Web of Science ®Google Scholar
• McNamara CR, Degterev A. Small-molecule inhibitors of the PI3K signaling network. Future Med Chem 2011;3(5):549-65
   PubMed Web of Science ®Google Scholar
• Wen PY, Lee EQ, Reardon DA, et al. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro-oncol 2012;14(7):819-29
   PubMed Web of Science ®Google Scholar
• Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012;10:161
   PubMed Web of Science ®Google Scholar
• Banham-Hall E, Clatworthy MR, Okkenhaug K. The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 2012;6:245-58
   PubMedGoogle Scholar
• Jackson SF, Schoenwaelder SM. Type I phosphoinositide 3-kinases: potential antithrombotic targets? Cell Mol Life Sci 2006;63(10):1085-90
   PubMed Web of Science ®Google Scholar
• Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005;11(5):507-14
   PubMed Web of Science ®Google Scholar
• Camps M, Ruckle T, Ji H, et al. Blockade of PI3K[gamma] suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005;11(9):936-43
   PubMed Web of Science ®Google Scholar
• Hayer S, Pundt N, Peters MA, et al. PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis. FASEB J 2009;23(12):4288-98
   PubMed Web of Science ®Google Scholar
• Rommel C, Camps M, Ji H. PI3K[delta] and PI3K[gamma]: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 2007;7(3):191-201
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003;3(4):317-30
   PubMed Web of Science ®Google Scholar
• So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J 2012;442(3):465-81
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9(8):550-62
   PubMed Web of Science ®Google Scholar
• Asensio CJ, Garcia RC. Determination of a large number of kinase activities using peptide substrates, P81 phosphocellulose paper arrays and phosphor imaging. Anal Biochem 2003;319(1):21-33
   PubMed Web of Science ®Google Scholar
• Ciraolo E, Perino A, Hirsch E. Measuring PI3K lipid kinase activity. Methods Mol Biol 2012;795:55-67
   PubMedGoogle Scholar
• Fuchikami K, Togame H, Sagara A, et al. A versatile high-throughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate assay for phosphoinositide 3-kinase gamma. J Biomol Screen 2002;7(5):441-50
   PubMed Web of Science ®Google Scholar
• Knight ZA, Feldman ME, Balla A, et al. A membrane capture assay for lipid kinase activity. Nat Protoc 2007;2(10):2459-66
   PubMed Web of Science ®Google Scholar
• Yanamandra M, Kole L, Giri A, et al. Development of phosphocellulose paper-based screening of inhibitors of lipid kinases: case study with PI3Kβ. Anal Biochem 2014;449:132-8
   PubMed Web of Science ®Google Scholar
• Yanamandra M, Kole L, Giri A, et al. ATP competition of PI3K inhibitors using phosphocellulose paper approach. Int J Bioassays 2014;3(09):3276-9
   Google Scholar
• Glickman JF, Schmid A, Ferrand S. Scintillation proximity assays in high-throughput screening. Assay Drug Dev Technol 2008;6(3):433-55
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Kaizawa H, Kawaguchi K, et al. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 2007;15(1):403-12
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 2006;14(20):6847-58
   PubMed Web of Science ®Google Scholar
• Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007;67(12):5840-50
   PubMed Web of Science ®Google Scholar
• Van Aller GS, Carson JD, Fernandes C, et al. Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay. Anal Biochem 2008;383(2):311-15
   PubMed Web of Science ®Google Scholar
• Lea WA, Simeonov A. Fluorescence polarization assays in small molecule screening. Expert Opin Drug Discov 2011;6(1):17-32
   PubMed Web of Science ®Google Scholar
• Echelon. PI3-Kinase Fluorescence Polarization Activity Assay. Available from: http://www.echelon-inc.com/content/EBI/product/files/TDS_K-1100_v5.pdf
   Google Scholar
• Horiuchi KY, Ma H. Fluorescence polarization and time-resolved fluorescence resonance energy transfer techniques for PI3K assays. Methods Mol Biol 2009;572:161-76
   PubMedGoogle Scholar
• Klink TA, Kleman-Leyer KM, Kopp A, et al. Evaluating PI3 kinase isoforms using Transcreener ADP assays. J Biomol Screen 2008;13(6):476-85
   PubMed Web of Science ®Google Scholar
• Degorce F, Card A, Soh S, et al. HTRF: a technology tailored for drug discovery - a review of theoretical aspects and recent applications. Curr Chem Genomics 2009;3:22-32
   PubMedGoogle Scholar
• Millipore. PI3K HTRF assay. Available from: http://www.emdmillipore.com/IN/en/product/PI-3-Kinase-HTRF%E2%84%A2-Assay%3B-1920-wells,MM_NF-33-017#anchor_DS
   Google Scholar
• Biochemical assays for selectivity profiling across the entire PI3 kinase family. Poster. Available from: http://tools.lifetechnologies.com/content/sfs/posters/0408-SBS-Biochem-Profiling-Across-PI3K-Family.pdf
   Google Scholar
• Huang W, Jiang D, Wang X, et al. Kinetic analysis of PI3K reactions with fluorescent PIP2 derivatives. Anal Bioanal Chem 2011;401(6):1881-8
   PubMed Web of Science ®Google Scholar
• Echelon. PI3-Kinase Activity ELISA: pico. Available from: http://www.echelon-inc.com/content/EBI/product/files/TDS_%20K-1000s_%20Rev%205x.pdf
   Google Scholar
• Millipore PI3 Kinase Activity/Inhibitor ELISA. Available from: http://www.merckmillipore.com/IN/en/product/PI3-Kinase-ActivityInhibitor-ELISA,MM_NF-17-493#anchor_UG
   Google Scholar
• Fan F, Wood KV. Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 2007;5(1):127-36
   PubMed Web of Science ®Google Scholar
• Promega. Technical manual of ADP-Glo™ Lipid Kinase Systems. Available from: http://www.promega.com/∼/media/files/resources/protocols/technical%20manuals/101/adp%20glo%20lipid%20kinase%20assay%20protocol.pdf
   Google Scholar
• Eglen RM, Reisine T, Roby P, et al. The use of AlphaScreen technology in HTS: current status. Curr Chem Genomics 2008;1:2-10
   PubMedGoogle Scholar
• Nehmé R, Nehmé H, Saurat T, et al. New in-capillary electrophoretic kinase assays to evaluate inhibitors of the PI3k/Akt/mTOR signaling pathway. Anal Bioanal Chem 2014;406(15):3743-54
   PubMed Web of Science ®Google Scholar
• Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 1993;296(Pt 2):297-301
   PubMed Web of Science ®Google Scholar
• Vlahos CJ, Matter WF, Hui KY, et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269(7):5241-8
   PubMed Web of Science ®Google Scholar
• Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996;16(4):1722-33
   PubMed Web of Science ®Google Scholar
• Ma H, Deacon S, Horiuchi K. The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discov 2008;3(6):607-21
   PubMed Web of Science ®Google Scholar
• Hastie CJ, McLauchlan HJ, Cohen P. Assay of protein kinases using radiolabeled ATP: a protocol. Nat Protoc 2006;1(2):968-71
   PubMed Web of Science ®Google Scholar
• Stankewicz C, Rininsland FH. A robust screen for inhibitors and enhancers of phosphoinositide-3 kinase (PI3K) activities by ratiometric fluorescence superquenching. J Biomol Screen 2006;11(4):413-22
   PubMed Web of Science ®Google Scholar
• Fernandez-Acero T, Rodriguez-Escudero I, Vicente F, et al. A yeast-based in vivo bioassay to screen for class I phosphatidylinositol 3-kinase specific inhibitors. J Biomol Screen 2012;17(8):1018-29
   PubMed Web of Science ®Google Scholar
• Lingaraj T, Donovan J, Li Z, et al. A high-throughput liposome substrate assay with automated lipid extraction process for PI 3-kinase. J Biomol Screen 2008;13(9):906-11
   PubMed Web of Science ®Google Scholar
• Demian DJ, Clugston SL, Foster MM, et al. High-throughput, cell-free, liposome-based approach for assessing in vitro activity of lipid kinases. J Biomol Screen 2009;14(7):838-44
   PubMed Web of Science ®Google Scholar
• Davis MI, Sasaki AT, Shen M, et al. A homogeneous, high-throughput assay for phosphatidylinositol 5-phosphate 4-kinase with a novel, rapid substrate preparation. PLoS One 2013;8(1):e54127
   PubMedGoogle Scholar
• Vidugiriene J, Zegzouti H, Goueli SA. Evaluating the utility of a bioluminescent ADP-detecting assay for lipid kinases. Assay Drug Dev Technol 2009;7(6):585-97
   PubMed Web of Science ®Google Scholar
• Deems RA. Interfacial enzyme kinetics at the phospholipid/water interface: practical considerations. Anal Biochem 2000;287(1):1-16
   PubMed Web of Science ®Google Scholar
• Jena Bioscience. Detection of PI3-Kinase activity using TLC mode of detection. Available from: http://www.jenabioscience.com/images/6a8b7ca1b0/PR-943.pdf
   Google Scholar
• Perkin Elmer. Scintillation Proximity Assay (SPA) applications. Available from: http://www.perkinelmer.com/pages/020/spaapplications/default.xhtml
   Google Scholar
• Life Technologies. Adapta® Universal Kinase Assay. Available from: http://www.lifetechnologies.com/in/en/home/life-science/drug-discovery/target-and-lead-identification-and-validation/kinasebiology/kinase-activity-assays/adapta-universal-kinase-assay.html#availability
   Google Scholar
• Bell Brook Labs. Application of the Transcreener™ Kinase Assay platform in evaluating PI3 lipid kinases. Available from: http://www.bellbrooklabs.com/PDFs/EZread_PI3kinase.pdf
   Google Scholar
• Echelon. AlphaScreen™ Assay for Detection and Quantification of PI3-Kinase Activity. Available from: http://www.echelon-inc.com/content/EBI/product/files/TDS_K-1300_Rev%2010.pdf
   Google Scholar